Mindray Medical – MR – To Acquire Controlling Stake in Dragonbio’s Orthopedics Business

Mindray Medical International Limited (NYSE:MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today a definitive agreement to acquire a controlling stake of Wuhan Dragonbio Surgical Implant Co., Ltd. (“Dragonbio”), a domestic medical orthopedic products provider that specializes in trauma, spine, joint and other surgical products. Under the agreement, Mindray will pay a total purchase price of approximately US$35.5 million, which will be funded through Mindray’s existing cash reserves. The transaction is expected to be closed in July. Mindray expects the deal to have minimal impact on its 2012 financial results and maintains its annual financial guidance on revenues and non-GAAP net income growth.

Founded in 2005 and based in Wuhan, China, Dragonbio sells medical orthopedic products solely in China and achieved total revenues of approximately US$7.7 million in 2011. Orthopedics is one of the largest medical device market segments worldwide. Based on Mindray’s estimates, the global orthopedic market was valued at approximately US$30 billion in 2011, with an annual growth rate of around 8%.  According to Frost & Sullivan, a research and consulting firm, the market size in China was approximately US$1.1 billion in 2010 and is rapidly growing with a projected CAGR of over 18% from 2010 to 2015.

Through the combined business benefits from the transaction, Mindray expects to gain access to the fast-growing Chinese orthopedic market and potentially expand into additional international markets in the future.

“We are excited about this transaction and are pleased to offer more products to our customers,” said Mr. Minghe Cheng, Mindray’s Chief Strategic Officer. “The orthopedic consumable market has high barriers to entry, but this deal will give us instant access to this promising and sizable market. We expect to unlock the value of the acquired business through our strong capital position, large-scale operational experience and worldwide presence.”

About Mindray – MR

MR is a leading developer, manufacturer and marketer of medical devices worldwide. MR maintains its global headquarters in Shenzhen, China, U.S. headquarters in Mahwah, New Jersey and multiple sales offices in major international markets.

MR – From our main manufacturing and engineering base in China, we supply through our worldwide distribution network a broad range of products across three primary business segments, namely patient monitoring and life support, in-vitro diagnostic, and medical imaging systems.

More Posts by this author

• 
  Stocks Headed for a Higher Finish
• 
  Gold Prices Marginally Higher; Silver Prices in Red
• 
  Stocks Rebound on Spain Rescue Hopes
• 
  General Dynamics – GD – Declares Dividend, Authorizes Share Repurchases
• 
  Agilysys – AGYS – Successfully repositioned the company
• 
  Rentrak – RENT – TV Essentials™ business grew 90 percent this quarter
• 
  Francesca’s Holdings – FRAN – FY12 is off to a strong start as we continue to execute on our differentiated business model

Post Written By: Ed Liston Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing in his yacht.